Scientific Advisory Board
Prof. Dr. Christoph Rader
Prof. Christoph Rader is Associate Professor with Tenure position in the Department of Cancer Biology and the Department of Molecular Therapeutics at The Scripps Research Institute (TSRI) in Jupiter, Florida, USA. Before this he was principal investigator at the National Cancer Institute (NCI) in Bethesda, Maryland, USA.
Prof. Rader studied biochemistry and molecular biology at the University of Bayreuth in Germany and at the University of Zurich in Switzerland, where he also obtained his PhD with honors in 1995 for work on immunoglobulin superfamily molecules. After this he did several years of postdoctoral research in the laboratory of Carlos F. Barbas III at TSRI in La Jolla, California, USA, where he specialized in antibody engineering, phage display, and catalytic antibody technologies. Following his promotion to Assistant Professor at TSRI, he won the prestigious Investigator Award from the Cancer Research Institute in 2000.
Prof. Rader’s work contributed to the invention of chemically programmed monoclonal antibodies, a cross between traditional small molecules and a certain monoclonal antibody. This innovation was subsequently commercialized, and is the basis for several new drugs currently in ongoing phase I and II clinical trials for the treatment of various cancers and metabolic diseases. Prof. Rader joined the NCI in 2003 to build and lead the Antibody Technology Section in the Experimental Transplantation and Immunology Branch. In 2007, he received the NCI Director's Intramural Innovation Award for Principal Investigators for a novel chemical programming concept.
His achievements include more than 80 publications and 13 patents or patent applications in the area of antibody engineering and antibody drug/toxin conjugation technologies.
Prof. Dr. Thomas Winkler
Prof. Thomas Winkler is Associate Professor for Genetics at the Nikolaus-Fiebinger Centre for Molecular Medicine of the University of Erlangen-Nuremberg, Germany, where his research focuses on understanding the genetic mechanisms for the early B-cell development and how defects in this may lead to loss of self-tolerance and the development of autoimmunity. In addition, his laboratory has a strong interest in understanding antibody- and B-lineage cell mediated protection against viral infections using cytomegalovirus as a model system in mice and in translational approaches for the benefit of patients.
Prof. Winkler has studied Biology at the University of Erlangen and did his PhD work in the laboratory of Prof. Jochen Kalden, a world-renowned rheumatologist and autoimmune Immunologist. After that he did post-doctoral work on B cell Immunology at the Basel Institute for Immunology, a triple Nobel-Prize awarded Swiss academic Institute. Following his post-doctoral research he became principal investigator at the Division of Molecular Medicine, at the University of Erlangen-Nuremberg, where in 2001 he was appointed Associate Professor for Genetics.
Prof. Winkler is a renowned Molecular Immunologist in the field of of research with antibody-producing B cells, and among other competitive grants has been awarded highly competivite Collaborative Research Centre (SFB) grants of the German Research Foundation, and of the Bavarian Immunotherapy Network (BayImmuNet: www.bayimmunet.de/en/).
Prof. Thomas Winkler has published several dozens scientific papers, including seminal papers in high-impact Journals, like Science, J. Exp. Med., PNAS, Immunity and Blood.
Prof. Dr. Alfred Zippelius
Prof. Alfred Zippelius, MD, is full Professor of Translational Oncology at the Departments of Medical Oncology and Biomedicine, Cancer Immunology at the University Hospital Basel, Switzerland. In these functions he is conducting clinical trials as well as supervising clinical research in his laboratory focusing on translational research in the area of cancer immunotherapy and the development of novel targeted cancer therapies.
Prof. Zippelius studied medicine at Ludwig-Maximilians-University (LMU) Munich, Germany, where he also performed experimental work for his MD thesis in the laboratory of world-renowned German Immunologist Prof. Dr. Gert Riethmüller. After this he performed post-doctoral research work as a German Research Agency (DFG)/Emmy-Noether fellow at the Ludwig Institute for Cancer Research (LICR) in Lausanne, Switzerland, and thereafter became principal investigator in the Tumor Immunology lab of the Medical Oncology Department at University Hospital Zurich, Switzerland. He was then appointed Swiss National Science Foundation (SNF) Professor and group leader of the Laboratory of Cancer Immunology, Department of Biomedicine, University of Basel, where he subsequently became full Professor of Translational Oncology. He has full responsibility for clinical trial design and applications and the research in the Laboratory of Cancer Immunology.
Prof. Zippelius is author of over 50 high-impact publications and inventor of several patents in the field of cancer immunology. During his career he has received numerous fellowships and awards, including competitive DFG/Emmy-Noether fellowship and SNF Professorships. Prof. Zippelius serves on a number of international review and advisory boards, including review functions at the Journal of Experimental Medicine, Blood, or PNAS, and the SNF, DFG and the Dutch Cancer Society. Prof. Zippelius is also active in many national and international professional societies, including the European Society for Medical Oncology (ESMO), the American Society for Clinical Oncology (ASCO) and the European Society for Cancer Immunology and Immunotherapy.
Dr. Anthony W. Tolcher
Dr. Anthony W. Tolcher, MD, is CEO, founder and Director of Clinical Research at NEXT Oncology in San Antonio, Texas, a phase I program with the mission to accelerate the development of the next breakthrough cure for cancer through high quality Phase I clinical and clinical pharmacology trials. In this function, Dr. Tolcher is coordinating and supervising clinical trials with novel targeted cancer therapies. Dr. Tolcher is a board-certified Medical Oncologist with an MD degree from the University of British Columbia, Vancouver, Canada. Dr. Tolcher specialized in Internal Medicine and Medical Oncology in residency programs at the University of Toronto and again at the University of British Columbia, respectively, before engaging in oncology research at the National Cancer Institute (NCI), National Institutes of Health (NIH) in Bethesda. He has held a staff position at the British Columbia Cancer Agency in Vancouver before moving to the Institute for Drug Development, Cancer Therapy and Research Center University of Texas Health Science Center in San Antonio where he became Director of Clinical Research in 1999, a position he held for almost 10 years. In 2007, Dr. Tolcher became co-founder and for a decade served as Director of Clinical Research at START (South Texas Accelerated Research Therapeutics) in San Antonio, TX, a global clinical trial organization enabling first-in-human clinical trials with innovative cancer drugs within a global network dedicated clinical trial sites in the U.S., Europe and in Asia. In this function, Dr. Tolcher has led and supervised many early-stage clinical trials with highly innovative, targeted cancer therapies, including antibody drug conjugates (ADCs). Dr. Tolcher is author or co-author of more than 130 peer-reviewed publications in the field of Medical and Clinical Oncology and an internationally renowned key opinion leader in the field of clinical validation of antibody drug conjugates.
- London, 2019-03-05 - NBE-Therapeutics will present at the 9th World ADC Congress Europe in London
- San Diego, USA, 2019-03-04 - NBE-Therapeutics invited to present at Terrapinn's Americas Antibody Congress
- Basel, 2019-01-29 - Unites States Patent and Trademark Office grants US patent on NBE's linker-toxin technology